NCT05197881

Daily Adaptive Radiation Therapy an Individualized Approach for Carcinoma of the Cervix

Daily Adaptive External Beam Radiation Therapy in the Treatment of Carcinoma of the Cervix: A Prospective Trial of an Individualized Approach for Intestinal Toxicity Reduction (ARTIA-Cervix)

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 125 (estimated)
• Sponsor: Varian, a Siemens Healthineers Company · Industry
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a single-arm, prospective, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for locally advanced cervical cancer will translate into a decreased rate of acute gastrointestinal toxicity compared with the historically reported rate for non-adaptive intensity modulated radiation therapy (IMRT). The timepoint for this assessment will be at week 5 of external beam radiotherapy (EBRT) and will use the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Conditions

• Cervical Cancer by FIGO Stage 2018

Interventions

Type	Name	Description
DEVICE	Varian Ethos Adaptive Radiation Therapy	Daily adaptive external beam radiation therapy delivered on Varian Ethos treatment system.

Timeline

• Start date: 2022-05-03
• Primary completion: 2028-09-01
• Completion: 2030-09-01
• First posted: 2022-01-20
• Last updated: 2025-09-23

Locations

5 sites across 1 country: United States

Regulatory

• FDA-regulated device study